Olmes Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmes Plus, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It treats hypertension in adults, often when lifestyle changes and monotherapy are insufficient.

GNH USA supplies Olmes Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmes Plus is an antihypertensive medication that acts on the renin‑angiotensin‑aldosterone system to lower blood pressure. - Essential hypertension: helps achieve target blood pressure when monotherapy is inadequate. - Hypertension with fluid retention: combines ARB action with diuretic effect to reduce volume overload. - Diabetic nephropathy risk reduction: provides blood pressure control that can slow kidney damage progression.

Olmes Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema involving face, lips or tongue - Liver enzyme elevation - Blood dyscrasias such as agranulocytosis

Before taking Olmes Plus, consider the following safety points: - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially when combined with other diuretics. - Pregnancy: avoid use during the second and third trimesters due to fetal toxicity. - Concomitant drugs: review other antihypertensives or potassium‑sparing agents for additive effects. - Gout: monitor uric acid as thiazides can precipitate gout attacks. Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmes Plus can interact with several medicines; careful management is recommended.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): may cause excessive renal impairment. - Lithium: increased risk of lithium toxicity. - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive blood‑pressure lowering and hyperkalemia risk. - Antidiabetic drugs: may require dose adjustment due to improved glycemic control.